ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Checkpoint Therapeutics Inc

Checkpoint Therapeutics Inc (CKPT)

1.80
-0.09
(-4.76%)
Closed June 22 4:00PM
1.80
-0.002
(-0.11%)
After Hours: 7:27PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.80
Bid
1.80
Ask
12.00
Volume
608,861
1.80 Day's Range 2.04
1.30 52 Week Range 3.62
Market Cap
Previous Close
1.89
Open
1.91
Last Trade
1
@
1.85
Last Trade Time
Financial Volume
$ 1,173,851
VWAP
1.9279
Average Volume (3m)
363,053
Shares Outstanding
36,850,279
Dividend Yield
-
PE Ratio
-1.28
Earnings Per Share (EPS)
-1.41
Revenue
103k
Net Profit
-51.85M

About Checkpoint Therapeutics Inc

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodie... Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
1970
Checkpoint Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CKPT. The last closing price for Checkpoint Therapeutics was $1.89. Over the last year, Checkpoint Therapeutics shares have traded in a share price range of $ 1.30 to $ 3.62.

Checkpoint Therapeutics currently has 36,850,279 shares outstanding. The market capitalization of Checkpoint Therapeutics is $66.33 million. Checkpoint Therapeutics has a price to earnings ratio (PE ratio) of -1.28.

CKPT Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.26-12.62135922332.062.21.83548522.01185641CS
4-0.04-2.173913043481.842.21.752658261.94458255CS
12-0.26-12.62135922332.062.21.383630531.75374154CS
26-0.03-1.63934426231.832.5851.385142191.93110988CS
52-0.83-31.55893536122.633.621.34741802.1016963CS
156-25.6-93.430656934327.446.41.357946516.13233839CS
260-38.954-95.583255631340.75453.7621.361941421.75789558CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SHCRSharecare Inc
$ 1.365
(76.27%)
56.33M
NXLNexalin Technologies Inc
$ 1.7499
(59.08%)
57.58M
FUFUBitFuFu Inc
$ 6.1209
(56.95%)
2.5M
SPECSpectaire Holdings Inc
$ 0.50
(47.06%)
65.27M
FLFVFeutune Light Acquisition Corporation
$ 2.5502
(-69.75%)
862.38k
FLFVUFeutune Light Acquisition Corporation
$ 2.75
(-66.83%)
16.5k
RWODRedwoods Acquisition Corporation
$ 2.34
(-60.34%)
155.96k
KAVLKaival Brands Innovations Group Inc
$ 1.23
(-57.14%)
4.92M
RWODURedwoods Acquisition Corporation
$ 3.24
(-56.28%)
1.47k
NVDANVIDIA Corporation
$ 126.57
(-3.22%)
658.13M
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SIRISirius XM Holdings Inc
$ 2.94
(1.38%)
330.66M
AAPLApple Inc
$ 207.49
(-1.04%)
246.38M
NKLANikola Corporation
$ 0.3466
(5.16%)
193.36M

CKPT Discussion

View Posts
vein vein 1 month ago
Waking up here ?? Any shareholders out there ??
๐Ÿ‘๏ธ0
glenn1919 glenn1919 2 months ago
CKPT......................................https://stockcharts.com/h-sc/ui?s=CKPT&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
vein vein 2 months ago
Seriously
๐Ÿ‘๏ธ0
chainma1l chainma1l 2 months ago
Dead money for quite a while. Maybe forever.
๐Ÿ‘๏ธ0
vein vein 2 months ago
Is this drug and company done ????
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
CKPT under $2
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 months ago
CKPT 10Q due March 7
๐Ÿ‘๏ธ0
chainma1l chainma1l 6 months ago
CKPT did a reverse split in the fairly recent past. I don't think that was in anticipation of anything specific other than selling additional shares in the future to raise money until they can generate some revenue. They were going to be selling shares whether or not they received the CRL. CRL just means they are going to be selling a LOT more shares than if they wouldn't have received it.
๐Ÿ‘๏ธ0
timberwolf7 timberwolf7 6 months ago
So did investors get a 'gift'?
Just heard about CKPT after the CRL came out. First comment is, resolution of the CRL could take longer than folks expect, just went thru it with CRMD and they got 2 CRLS due to the manufacturers QA issues (4 frigging years for the fda to agree to the 'fixes' and all the while the manufacturers were ALLOWED to continue operations under the fda umbrella, someone explain that one)

Anyways, so looking into CKPT, like the low share count, don't like the low cash on hand cause can only read it to mean, thanks to the delay, they will likely need to conduct a cash raising operation (ATM or flat out secondary). CRMD had to do this and it really cut their target price down.

So, just thought I would check in, see what folks are saying, and quite frankly, a bit surprised given its a cancer related treatment, given how the market is pricing so many bios as if they are selling gold, that CKPT was where it was on the share price..

But going to be studying their trial analysis, how good they see it working. And really tired of the fda holding up drug approvals for drugs that CAN/WOULD help save lives vs delaying the approval especially if it worked. Now I wouldn't be as 'upset' at the fda if as in this case, they tell the manufacturer, since you are bad enough for us not to approve a potential life saving drug, your operations are totally suspended.
Otherwise, to me, the fda has its priorities screwed up.. when it allows operations to continue.. but puts a life saving drug into limbo land.. again, CRMD has something going for it, hell of a lot better than the current standard of care, but was delayed 4 frigging years over QA issues.

Good luck
๐Ÿ‘๏ธ0
vein vein 6 months ago
Stupid
๐Ÿ‘๏ธ0
vein vein 7 months ago
Wouldnโ€™t mind seeing a partner for launch !!
๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
Always a concern with start up biomeds
๐Ÿ‘๏ธ0
vein vein 7 months ago
Chart must look pretty good here . I wonder if another offering is coming ??
๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
The positives continue
๐Ÿ‘๏ธ0
vein vein 7 months ago
Patent news is cool.
๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
Been awhile so lets update the chart
๐Ÿ‘๏ธ0
vein vein 7 months ago
Letโ€™s make a run into approval !!
๐Ÿ‘๏ธ0
Monksdream Monksdream 9 months ago
CKPT under $2
๐Ÿ‘๏ธ0
Monksdream Monksdream 9 months ago
CKPT new 52 week low
๐Ÿ‘๏ธ0
timung timung 11 months ago
CKPT https://www.tipranks.com/news/blurbs/b-riley-financial-sticks-to-their-buy-rating-for-checkpoint-therapeutics-ckpt
๐Ÿ‘๏ธ0
timung timung 11 months ago
CKPT https://www.tipranks.com/news/blurbs/lake-street-keeps-their-buy-rating-on-checkpoint-therapeutics-ckpt
๐Ÿ‘๏ธ0
timung timung 11 months ago
ckpt https://www.tipranks.com/news/blurbs/b-riley-financial-sticks-to-their-buy-rating-for-checkpoint-therapeutics-ckpt
๐Ÿ‘๏ธ0
tw0122 tw0122 11 months ago
Biologics License Application currently under review by U.S. FDA; PDUFA goal date of January 3, 2024

WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (โ€œCheckpointโ€) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced new, longer-term data for cosibelimab from its pivotal studies in locally advanced and metastatic cutaneous squamous cell carcinoma (โ€œcSCCโ€). These results demonstrate a deepening of response over time, resulting in substantially higher complete response rates than previously reported. Furthermore, responses continue to remain durable over time with the median duration of response not yet reached in either group. Results determined by independent central review by treatment group were as follows:


Parametera Locally Advanced cSCC
(n=31) Metastatic cSCC
(n=78)
Data cutoff Mar 2022 Jan 2023 Nov 2021 Jan 2023
Objective response rate
(95% confidence interval) 55%
(36%, 73%) 55%
(36%, 73%) 47%
(36%, 59%) 50%
(39%, 62%)
Complete response rate 10 % 23 % 8 % 13 %
Partial response rate 45 % 32 % 39 % 37 %
Response ongoing 82 % 82 % 73 % 69 %
Median duration of response Not reached Not reached Not reached Not reached
a As assessed by independent central review.

โ€œWe are excited to see the substantial increases in the rate of patients experiencing a complete response of their cSCC tumors with further cosibelimab treatment in both our locally advanced and metastatic pivotal trials,โ€ said James Oliviero, President and Chief Executive Officer of Checkpoint. โ€œWe believe cosibelimabโ€™s strong efficacy and response durability are driven by its unique two-fold mechanism of action in which cosibelimab binds to PD-L1 with sustained high target tumor occupancy to reactivate the bodyโ€™s T-cell anti-tumor response, with the addition of a functional Fc domain to activate the bodyโ€™s natural killer immune cells to induce antibody-dependent cell-mediated cytotoxicity of tumor cells, resulting in a powerful one-two punch to eradicate tumors. We expect this dual mechanism of action to benefit not just immunocompetent patients, but also the large number of difficult-to-treat patients with immunosuppressive conditions or taking immunosuppressive medications who continue to suffer poor outcomes with currently available treatments.โ€

Updated safety data across 247 patients enrolled and treated with cosibelimab in all cohorts of the ongoing study remain consistent with those previously reported, with only 2% of patients experiencing a severe immune-related adverse event (โ€œirAEโ€) and less than 1% of patients discontinuing treatment due to an irAE of any severity, both substantially lower than the rates observed with currently approved immunotherapies.

Mr. Oliviero continued, โ€œUnlike PD-1 inhibitors, cosibelimab does not interrupt the bodyโ€™s PD-1/PD-L2 pathway, which we believe results in cosibelimabโ€™s low rates of autoimmunity. We believe cosibelimabโ€™s favorable safety profile should position the product as the preferred immunotherapy of oncologists for the large number of high-risk cSCC patients, such as those with solid organ transplants or autoimmune disease, upon its potential launch early next year. If our Biologics License Application (โ€œBLAโ€) is approved in the coming months, based on its unique mechanism of action and compelling efficacy and safety profile, we believe cosibelimab, as a differentiated and possibly best-in-class treatment, has the potential to become the market leading immunotherapy for patients with cSCC, which we estimate to be a $1.6 billion annual U.S. market opportunity.โ€

In January 2023, Checkpoint submitted a BLA to the U.S. Food and Drug Administration (โ€œFDAโ€) seeking approval of cosibelimab as a treatment for patients with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or radiation. The application is filed and under review with a Prescription Drug User Fee Act (โ€œPDUFAโ€) goal date of January 3, 2024.

Checkpoint plans to present these updated results at an upcoming medical conference.

๐Ÿ‘๏ธ0
vein vein 1 year ago
We can only hope !!!
๐Ÿ‘๏ธ0
chainma1l chainma1l 1 year ago
Does that $10 million get them to PDUFA? Seems like chump change. I'm guessing they are hoping they can raise some more money once the stock starts to push up as PDUFA gets closer.
๐Ÿ‘๏ธ0
glenn1919 glenn1919 1 year ago
CKPT............................https://stockcharts.com/h-sc/ui?s=CKPT&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
glenn1919 glenn1919 1 year ago
CKPT.......................https://stockcharts.com/h-sc/ui?s=CKPT&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
glenn1919 glenn1919 1 year ago
CKPT.....................https://stockcharts.com/h-sc/ui?s=CKPT&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
vein vein 1 year ago
This stock sure is volatile!!
๐Ÿ‘๏ธ0
vein vein 1 year ago
Yeah , especially with the rise in stock price
๐Ÿ‘๏ธ0
Monroe1 Monroe1 1 year ago
Looks to me like they will have to do another stock offering. I think they have enough cash to last until June.
๐Ÿ‘๏ธ0
vein vein 1 year ago
Market still only 80 million
๐Ÿ‘๏ธ0
vein vein 1 year ago
Do we think another stock offering here soon ?? Iโ€™m sure they could use the cash
๐Ÿ‘๏ธ0
Monroe1 Monroe1 1 year ago
a recent holding split... medi wound, and now up 800%. sold before the split and did not buy back in. made some bucks but really missed out on the upswing.
๐Ÿ‘๏ธ0
Monroe1 Monroe1 1 year ago
Good point to remember. Big moves are quite possible. And anything is possible especially for the real big time insiders. Unfair to have such competition I say.

https://www.theblaze.com/news/moderna-neglected-to-share-damning-data-about-its-new-booster-shot
๐Ÿ‘๏ธ0
vein vein 1 year ago
When you think about it, our market cap is still tiny !!!
๐Ÿ‘๏ธ0
vein vein 1 year ago
Yeah , just hope we hold on to some of the gains !!!
๐Ÿ‘๏ธ0
Monroe1 Monroe1 1 year ago
This happened to me on another ticker. Last month it RS'd and now up 45%.
Just goes to show a RS does not always spell doom. After all, it leads to new investors and sometimes to a higher exchange or platform like QB or Nasdaq/NYSE/Amex and later to increasing the AS and raising money for expansion.
๐Ÿ‘๏ธ0
vein vein 1 year ago
Should have scooped up after the split ??
๐Ÿ‘๏ธ0
Monroe1 Monroe1 1 year ago
very few left. looking to re enter.
๐Ÿ‘๏ธ0
vein vein 1 year ago
Thanks for the input Monroe ! You still own shares ???
๐Ÿ‘๏ธ0
Monroe1 Monroe1 1 year ago
Looks to me like a Director has converted half or so of their preferred into common stock which often is done before a run up on the pps of common. Look for events to be forth coming. IMO
๐Ÿ‘๏ธ0
vein vein 1 year ago
Hey Monroe , whatโ€™s the form 4 mean that was presented after hours from fortress biotech ??
๐Ÿ‘๏ธ0
Monroe1 Monroe1 1 year ago
Checkpoint Therapeutics Submits Biologics License Application for Skin Cancer Therapy

MT NEWSWIRES

11:27 AM ET 01/04/2023

11:27 AM EST, 01/04/2023 (MT Newswires) -- Checkpoint Therapeutics (CKPT) said Wednesday it has submitted a biologics license application to the US Food and Drug Administration for the approval of cosibelimab to treat patients with metastatic cutaneous squamous cell carcinoma or locally advanced cSCC who are not candidates for curative surgery or radiation.

The application is backed by positive efficacy and safety data from its ongoing trial of cosibelimab, the company said.

Shares of Checkpoint Therapeutics (CKPT) rose more than 6% in recent trading activity.
๐Ÿ‘๏ธ0
vein vein 1 year ago
Iโ€™m stating to wish I added after the reverse split !!
๐Ÿ‘๏ธ0
vein vein 1 year ago
There is the BLA
๐Ÿ‘๏ธ0
Monroe1 Monroe1 1 year ago
wow, just got back home, nice gain!
๐Ÿ‘๏ธ0
chainma1l chainma1l 1 year ago
Sure seems that way. I should have bought at the low.
๐Ÿ‘๏ธ0
vein vein 1 year ago
BLA on the way ??
๐Ÿ‘๏ธ0
vein vein 1 year ago
2023
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock